1.2 OMIM# of the disease 305400.
1.3 Name of the analysed genes or DNA/chromosome segments FGD1.
Variation locations are based on the following accessions: NCBI Reference Sequence: NC_000023.11, NG_008054.1, NM_004463.2, NP_004454.2.
UniProtKB/Swiss-Prot: FGD1_HUMAN, P98174. Ensamble: FGD1 Gene ENSG00000102302. Transcript FGD1-001 ENST00000375135.
Exons are numbered from 1 to 18, starting at the translation initiation site, according to the previously published gene structure. 1 1.4 OMIM# of the gene(s) 300546.
Spectrum of sequence variants
Missense, nonsense, deletions and insertions are reported in addition to gross rearrangements. No variant hotspots or common variants are seen with the majority of variants being unique within families. Lists of disease-causing variants can be found at www.lovd. nl/FGD1 (Leiden Open Variation Database) and www.hgmd.cf.ac. uk/ac/index.php (Human Genoma database at the Institute of Medical Genetics in Cardiff). To the best of our knowledge, incorporating information from published articles, unpublished data and congress reports, 61 variants have been characterized. These comprise 32 missense variants, 16 frameshift variants, 6 nonsense variants, 4 splice site variants, 1 in-frame deletion and 2 gross deletions. [2] [3] [4] [5] [6] [7] [8] [9] [10] In addition, a large duplication (exon 2-12) and a branch-point variant, both leading to a premature stop codon, have been described in affected families. 11, 12 Germline mosaicism has been reported. 6 No definite genotype-phenotype correlation is apparent from comparison of patients with different variants; 2, 10 however, affected members of one family with a c.1341G4A; p.(Trp447Ter) variant in exon 6 all presented with additional signs of myopathy and distal arthropathy. 8 
Analytical methods
Gene sequencing provides the most common technical approach for detection of sequence variants. MLPA (multiplex ligation-dependent probe amplification) kits for detection of deletions/duplications of one or more exons of the FGD1 gene are commercially available. Sequence variants have also been detected using a whole-exome sequencing approach, in the past, 12 and next-generation sequencing technologies are expected to rapidly accelerate the detection of causal variants in this condition in the future.
Analytical validation
This is undertaken by analysis of independent control samples for the presumed pathogenic variant found in affected individuals, comparison to database entries and published data, and testing of other affected/ unaffected relatives in the family to see if the variant segregates with the disease. These approaches will facilitate the distinction of pathogenic variants from polymorphisms, especially in the cases of missense variants 1.8 Estimated frequency of the disease (incidence at birth ('birth prevalence') or population prevalence) Only 35 molecularly proven cases have been published worldwide. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] The majority of patients with a clinical diagnosis where details were published before the advent of molecular testing have not undergone subsequent molecular testing. Experience in Leuven (Prof. JP Fryns: personal communication), a typical-sized clinical genetics unit, suggests that two to three new patients with a proven variant in the FGD1 gene will be identified per year, a similar number as for Angelman and Prader-Willi syndrome. This gives an estimated population prevalence of AAS, which is equal to or slightly lower than to 1/25 000.
If applicable, prevalence in different ethnic groups:
Not applicable. The majority of individuals and families who have been studied molecularly to date are all of Caucasian extract (USA and Europe).
Diagnostic setting
This is not applicable as the signs of AAS are usually present in childhood and genetic testing, even in young children, is considered diagnostic and not predictive. Prenatal testing -see further (3.4) for considerations regarding prenatal diagnosis. 
TEST CHARACTERISTICS

Clinical sensitivity (proportion of positive tests if the disease is present)
Approximately 22%. 1 To estimate the highest variant detection rate, only affected individuals who fully meet the classical diagnostic criteria for AAS should be taken into account. 1 Testing only this group will, however, limit the probability of detecting pathogenic variants in less typical patients, who may represent broader clinical subtypes of AAS. It is already acknowledged that some patients with pathogenic variants do not have all the typical clinical features. [13] [14] [15] The clinical sensitivity depends on variable factors such as age or family history. In reporting cases, a general statement to this effect should be given, even if a quantification can only be made case by case. Failure to detect a likely pathogenic variant in most patients referred for FGD1 analysis is likely to be largely attributable to the clinical and genetic heterogeneity of AAS and the fact that the clinical features overlap with those of several other disorders. Noonan syndrome in particular shows significant clinical overlap with short stature, hypertelorism, genital anomalies and ptosis. Other differential diagnoses include SHORT syndrome, pseudohypoparathyroidism and Robinow syndrome.
Especially the latter condition presents with many clinical similarities (short stature, hypertelorism, facial features). However, these individuals never have a 'shawl scrotum', while a mesomelic limb shortening represents a main typical feature of Robinow syndrome not described in the AAS.
Most of the disorders with overlapping features with AAS (hypertelorism, short stature, brachydactyly, male genital abnormalities) may be differentiated on clinical basis and addressed to specific genetic testing. However, as differences may not always be obvious, a possible targeted NGS approach in similar cases might be indicated and, in addiction to FGD1, should also include ROR2 and WNT5A, genes known to be involved in the pathogenesis of the Robinow syndrome. 16, 17 
Clinical specificity (proportion of negative tests if the disease is not present)
The clinical specificity can be dependent on variable factors such as age or family history. When reporting, a general statement should be given, even if a quantification can only be made case by case. 100%.
Positive clinical predictive value (life-time risk of developing the disease if the test is positive)
Not applicable: see comment to the point 1.10 'D' about predictive tests.
Negative clinical predictive value (probability of not developing the disease if the test is negative)
Assume an increased risk based on family history for a non-affected person. Allelic and locus heterogeneity may need to be considered in individuals who test negative.
Index case in that family had been tested: Not applicable (due to genetic heterogeneity). Index case in that family had not been tested: Not applicable. There are no specific therapies for AAS. Some features (hypospadias, inguinal or umbilical hernias, cryptorchidism and unusually severe craniofacial features) may need surgical intervention. 15 Radiological assessment of the cervical spine should be carried out, with orthopaedic referral if necessary, as compression of cervical nerve roots may be the consequence of cervical vertebral defects (hypoplasia of the first cervical vertebra, unfused posterior arch, synostosis, anomaly of the odontoid). 18 The effect of growth hormone (GH) treatment on height gain has been reported only in preliminary studies and needs confirmation. 19 In the case of neurodevelopmental symptoms, generally mild intellectual disability and attention deficit and hyperactivity disorder (ADHD), a neuropsychiatric opinion and input may be useful. 20, 21 Prognosis (please describe)
CLINICAL UTILITY
Due to the clinical and genetic heterogeneity, the identification of an FGD1 variant in an AAS patient will not lead to an altered prognosis, when compared with patients in whom a variant was not found. 
Prenatal diagnosis
(To be answered if in 1.10 'D' was marked).
3.4.1 Does a positive genetic test result in the index patient enable a prenatal diagnosis? Prenatal diagnosis for pregnancies at increased risk is possible when the disease-causing variant in the family has been identified. However, in practice, prenatal testing is unlikely to be requested frequently as even in male patients physical signs can be mild and the broad variability of clinical expression in an individual family makes prediction of the phenotype difficult. 22 
IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
Please assume that the result of a genetic test has no immediate medical consequences. Is there any evidence that a genetic test is nevertheless useful for the patient or his/her relatives? (Please describe) The result of an FGD1 genetic test may have no immediate medical consequences for the affected individual and their family, but having a positive molecular genetic diagnosis will influence genetic counselling and may influence reproductive decisions. It is likely that relatives will consider genetic counselling and carrier testing to assess their own risks. In many cases a positive FGD1 test has removed the need for further diagnostic investigations.
